(GLUE) Monte Rosa Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.521m USD | Total Return: 364.4% in 12m

Molecular Glue Degraders, Small Molecules, Precision Medicines, Discovery Engine
Total Rating 40
Safety 34
Buy Signal -0.26
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.52B
Avg Turnover: 12.7M
Risk 3d forecast
Volatility89.9%
VaR 5th Pctl14.0%
VaR vs Median-5.37%
Reward TTM
Sharpe Ratio2.05
Rel. Str. IBD97.2
Rel. Str. Peer Group87.8
Character TTM
Beta1.979
Beta Downside1.335
Hurst Exponent0.395
Drawdowns 3y
Max DD67.19%
CAGR/Max DD0.69
CAGR/Mean DD1.44
EPS (Earnings per Share) EPS (Earnings per Share) of GLUE over the last years for every Quarter: "2021-03": -3.06, "2021-06": -3.63, "2021-09": -0.43, "2021-12": -0.93, "2022-03": -0.51, "2022-06": -0.57, "2022-09": -0.58, "2022-12": -0.63, "2023-03": -0.65, "2023-06": -0.71, "2023-09": -0.7, "2023-12": -0.58, "2024-03": -0.53, "2024-06": -0.43, "2024-09": -0.29, "2024-12": -0.3581, "2025-03": 0.57, "2025-06": -0.15, "2025-09": -0.33, "2025-12": -0.55, "2026-03": -0.45,
Last SUE: 0.06
Qual. Beats: 0
Revenue Revenue of GLUE over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 8.752, 2024-03: 1.064, 2024-06: 4.695, 2024-09: 9.216, 2024-12: 60.647, 2025-03: 84.929, 2025-06: 23.194, 2025-09: 12.768, 2025-12: 2.781, 2026-03: 4.21,
Last SUE: -0.28
Qual. Beats: 0

Warnings

High Debt while negative Cash Flow

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' -1.25 < 1.0 - financial distress zone

Fakeout Below Avwap Earnings

Tailwinds

Leader

Description: GLUE Monte Rosa Therapeutics

Monte Rosa Therapeutics (GLUE) is a clinical-stage biotechnology firm specializing in molecular glue degraders (MGDs). These small molecule medicines are designed to utilize cellular machinery to selectively eliminate disease-causing proteins that were previously considered undruggable. The company’s proprietary QuEEN platform serves as a discovery engine to identify and develop these candidates across oncology, immunology, and inflammation.

The biotechnology sector often relies on strategic partnerships to fund capital-intensive research and development. Monte Rosa maintains significant collaboration and licensing agreements with global pharmaceutical leaders Novartis and F. Hoffmann-La Roche Ltd. to advance its pipeline. The companys lead candidates, including MRT-2359 and MRT-6160, target specific genetic drivers of tumors and systemic autoimmune diseases.

For a detailed analysis of the companys valuation and risk profile, consider reviewing the latest reports on ValueRay. Monte Rosa operates within the high-risk, high-reward biotechnology landscape, where clinical trial outcomes and regulatory milestones are the primary drivers of shareholder value.

Headlines to Watch Out For
  • Novartis collaboration milestones and royalty potential drive near-term cash runway
  • Clinical trial data for MRT-2359 determines viability in MYC-driven solid tumors
  • Expansion of QuEEN discovery platform validates long-term molecular glue pipeline
  • Regulatory progress for MRT-6160 influences sentiment in autoimmune and inflammatory markets
  • High research and development expenditures necessitate continued access to capital markets
Piotroski VR-10 (Strict) 2.0
Net Income: -130.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.15 > 0.02 and ΔFCF/TA -22.74 > 1.0
NWC/Revenue: 1.41k% < 20% (prev 171.2%; Δ 1.24k% < -1%)
CFO/TA -0.02 > 3% & CFO -14.7m > Net Income -130.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.54 > 1.5 & < 3
Outstanding Shares: last quarter (65.5m) vs 12m ago -20.99% < -2%
Gross Margin: 80.59% > 18% (prev 0.96%; Δ 7.96k% > 0.5%)
Asset Turnover: 7.60% > 50% (prev 40.56%; Δ -32.96% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -1.25
A: 0.82 (Total Current Assets 677.5m - Total Current Liabilities 71.0m) / Total Assets 736.4m
B: -0.71 (Retained Earnings -521.7m / Total Assets 736.4m)
C: -0.26 (EBIT TTM -148.3m / Avg Total Assets 564.8m)
D: -2.45 (Book Value of Equity -526.5m / Total Liabilities 214.5m)
Altman-Z'' = -1.25 = CCC
Beneish M 1.00
DSRI: 12.15 (Receivables 4.61m/1.41m, Revenue 43.0m/159.5m)
GMI: 1.19 (GM 80.59% / 96.10%)
AQI: 0.58 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: 0.27 (Revenue 43.0m / 159.5m)
TATA: -0.16 (NI -130.0m - CFO -14.7m) / TA 736.4m)
Beneish M = 5.39 (Cap -4..+1) = D
What is the price of GLUE shares?

As of May 24, 2026, the stock is trading at USD 18.88 with a total of 758,637 shares traded.
Over the past week, the price has changed by +3.64%, over one month by -10.34%, over three months by -3.59% and over the past year by +364.44%.

Is GLUE a buy, sell or hold?

Monte Rosa Therapeutics has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy GLUE.

  • StrongBuy: 6
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the GLUE price?
Analysts Target Price 32.3 71.2%
Monte Rosa Therapeutics (GLUE) - Fundamental Data Overview as of 20 May 2026
P/E Forward = 10.8578
P/S = 35.4218
P/B = 2.9168
Revenue TTM = 43.0m USD
EBIT TTM = -148.3m USD
EBITDA TTM = -139.9m USD
Long Term Debt = 34.6m USD (estimated: total debt 39.1m - short term 4.48m)
Short Term Debt = 4.48m USD (from shortTermDebt, last quarter)
Debt = 39.1m USD (from shortLongTermDebtTotal, last quarter) (leases 39.2m already included)
Net Debt = -521.9m USD (calculated: Debt 39.1m - CCE 561.0m)
Enterprise Value = 999.6m USD (1.52b + Debt 39.1m - CCE 561.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -148.3m / Interest Expense TTM 0.0)
 EV/FCF = -8.89x (Enterprise Value 999.6m / FCF TTM -112.5m)
FCF Yield = -11.25% (FCF TTM -112.5m / Enterprise Value 999.6m)
 FCF Margin = -261.8% (FCF TTM -112.5m / Revenue TTM 43.0m)
 Net Margin = -302.7% (Net Income TTM -130.0m / Revenue TTM 43.0m)
 Gross Margin = 80.59% ((Revenue TTM 43.0m - Cost of Revenue TTM 8.34m) / Revenue TTM)
Gross Margin QoQ = 51.81% (prev 24.92%)
Tobins Q-Ratio = 1.36 (Enterprise Value 999.6m / Total Assets 736.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 39.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -117.1m (EBIT -148.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.58 (Total Current Assets 677.5m / Total Current Liabilities 78.9m)
Debt / Equity = 0.07 (Debt 39.1m / totalStockholderEquity, last quarter 521.9m)
 Debt / EBITDA = 3.73 (negative EBITDA) (Net Debt -521.9m / EBITDA -139.9m)
 Debt / FCF = 4.64 (negative FCF - burning cash) (Net Debt -521.9m / FCF TTM -112.5m)
 Total Stockholder Equity = 317.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.02% (Net Income -130.0m / Total Assets 736.4m)
RoE = -15.50% (Net Income TTM -130.0m / Total Stockholder Equity 838.9m)
RoCE = -16.97% (EBIT -148.3m / Capital Employed (Equity 838.9m + L.T.Debt 34.6m))
 RoIC = -17.49% (negative operating profit) (NOPAT -117.1m / Invested Capital 669.9m)
 WACC = 12.62% (E(1.52b)/V(1.56b) * Re(12.94%) + D(39.1m)/V(1.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 35.96 | Cagr: 6.46%
 [DCF] Fair Price = unknown (Cash Flow -112.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.06 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.37 | Chg30d=-1.08% | Revisions=+0% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.38 | Chg30d=+0.99% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.59 | Chg30d=-10.82% | Revisions=-20% | GrowthEPS=-246.1% | GrowthRev=-64.0%
EPS next Year (2027-12-31): EPS=-1.81 | Chg30d=-8.65% | Revisions=-20% | GrowthEPS=-14.0% | GrowthRev=+30.9%
[Analyst] Revisions Ratio: -20%